Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 16;13(8):2303.
doi: 10.3390/jcm13082303.

Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic

Pavel Dlouhý  1 , Cyril Mucha  2 , Lenka Mokrá  3 , Matyáš Kuhn  3 , Lenka Hrdlickova  4 , Urs Arnet  5 , Yohance Whiteside  6
Affiliations

Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic

Pavel Dlouhý et al. J Clin Med. .

Abstract

Background/Objectives: Molnupiravir (MOV), an oral antiviral COVID-19 treatment, was introduced in the Czech Republic in December 2021 for COVID-19 patients at a high risk of progression to severe disease requiring hospitalization. In this observational, retrospective study, we aimed to describe the characteristics and healthcare resource utilization in non-hospitalized, adult COVID-19 patients prescribed MOV in the Czech Republic between 1 January and 30 April 2022. Methods: A total of 621 patients were included and followed up with for 28 days. Results: The median age was 68.0 (20-99) years, 77.8% were overweight or obese, 14.1% smoked, and 85.7% were vaccinated. The overall cumulative incidence (95% CI) of all-cause hospitalization was 0.71 (0.37; 1.24) per 1000 person years or 1.9%, with similar rates across sexes, age groups, BMI category, multimorbidity category, polypharmacy category, and COVID-19 vaccination status. Among patients reported hospitalized, oxygen-based resources were not observed, and no deaths occurred. Conclusions: These data describe the characteristics and healthcare resource utilization in Czech MOV-treated patients whose clinical characteristics may put them at increased risk of severe disease.

Keywords: COVID-19; Czech Republic; SARS-CoV-2; molnupiravir; real-world data; treatment of COVID-19.

PubMed Disclaimer

Conflict of interest statement

Lenka Mokrá and Matyáš Kuhn were employed by the company Institute of Biostatistics and Analyses, Ltd., Urs Arnet, Lenka Hrdličková, and Yohance Whiteside are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and are shareholders in Merck & Co., Inc., Rahway, NJ, USA.

References

    1. WHO . WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19. WHO; Geneva, Switzerland: 2020.
    1. Cucinotta D., Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91:157–160. doi: 10.23750/abm.v91i1.9397. - DOI - PMC - PubMed
    1. Statement on the Fifteenth Meeting of the IHR (2005) Emergency Committee on the COVID-19 Pandemic. [(accessed on 12 May 2023)]. Available online: https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meet....
    1. [(accessed on 12 May 2023)]. Available online: https://covid19.who.int/
    1. Nurchis M.C., Pascucci D., Sapienza M., Villani L., D’Ambrosio F., Castrini F., Specchia M.L., Laurenti P., Damiani G. Impact of the Burden of COVID-19 in Italy: Results of Disability-Adjusted Life Years (DALYs) and Productivity Loss. Int. J. Environ. Res. Public Health. 2020;17:4233. doi: 10.3390/ijerph17124233. - DOI - PMC - PubMed

LinkOut - more resources